This study is a prospective, randomized, open-label, multicenter phase II trial in order to
determine progression-free survival of patients with refractory or relapsed metastatic
uterine leiomyosarcomas or other metastatic uterine tumours.
Phase:
Phase 2
Details
Lead Sponsor:
North Eastern German Society of Gynaecological Oncology University Medicine Greifswald